On February 20, 2026 Rakovina Therapeutics Inc. (TSX-V: RKV)(FSE: 7JO0) ("Rakovina" or the "Company"), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, reported that its previously announced financing has been upsized up to approximately $2 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On January 27th, the Company announced that it has reached an agreement in principle with an existing investor to invest an additional $1.0 million in the Company by way of a non-brokered private placement (the "Debenture Private Placement") of an unsecured convertible debenture and two million common share purchase warrants. The Company anticipates that key terms of the convertible debenture would include:

a maturity date of January 28, 2029;
a conversion price of $0.20 per common share; and
an interest rate of 12% per annum payable semi-annually in cash.
Each warrant would be exercisable at $0.20 per common share until January 28, 2029, subject to customary adjustments. A subsequent news release will be issued in connection with the Debenture Private Placement once financing terms have been finalized.

Concurrently with the Debenture Private Placement, the Company proposes to offer up to 8,333,334 common shares at a price of $0.12 per share for additional gross proceeds of up to approximately $1.0 million by way of a non-brokered private placement (the "Common Share Private Placement" and, together with the Debenture Private Placement, the "Private Placements"). As consideration for services provided in connection with the Common Share Private Placement, the Company may pay a finder’s fee to certain eligible finders who introduce subscribers to the financing.

The terms of the Private Placements, as announced in the Company’s news release dated January 27, 2026, otherwise remain unchanged.

The Company intends to use the aggregate gross proceeds of the Private Placements to provide near-term working capital to support ongoing corporate activities and strategic initiatives while the Company continues to evaluate longer-term financing alternatives.

Closing of the Private Placements is subject to the Company obtaining all necessary corporate and regulatory approvals, including approval of the TSX Venture Exchange, and entry into definitive subscription agreements. Pursuant to applicable Canadian securities laws, all securities issued in connection with the Private Placements will be subject to a statutory hold period of four months plus a day from the date of issuance.

(Press release, Rakovina Therapeutics, FEB 20, 2026, View Source;utm_medium=rss&utm_campaign=rakovina-therapeutics-announces-upsized-financing-up-to-2-0-million [SID1234662860])

On February 19, 2026 Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), reported it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,122,652 shares of common stock of the Company at an exercise price of $3.90 per share. The issuance or resale of the shares of common stock issuable upon exercise of the outstanding warrants has been registered pursuant to effective registration statements. The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $8.3 million, before deducting financial advisory fees.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Roth Capital Partners is acting as the Company’s financial advisor for this transaction.

In consideration for the immediate exercise of the warrants for cash, the Company will issue new unregistered warrants to purchase shares of common stock. The new warrants will be exercisable for an aggregate of up to 6,367,956 shares of common stock, at an exercise price equal to the lesser of $3.90 per share or the lowest volume weighted average price of the Company’s common stock on any trading day during the next five trading days, will be exercisable upon shareholder approval and for a term of five years from the date of shareholder approval.

The transaction is expected to close on or about February 20, 2026, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.

The new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the "1933 Act") and, along with the shares of common stock issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission ("SEC") or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the new warrants.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

(Press release, Moleculin, FEB 19, 2026, View Source [SID1234662787])

On February 19, 2026 Ten63 Therapeutics, an advanced AI drug-discovery company, reported that it added strategic investment from new investors Chugai Venture Fund and the Gates Foundation, bringing the Company’s total funding to over $45M.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are very impressed with Ten63’s AI drug discovery platform and its ability to quickly and accurately simulate trillions of potential drugs," said John Gustofson, President and Head of Chugai Venture Fund. "However, this is not just about making drug discovery faster. It’s about creating medicines for targets no one else can and designing better alternatives where existing drugs deliver inadequate results."

The increased funding will fuel the advancement of Ten63’s proprietary computational drug discovery platform, BEYOND. BEYOND is the world’s first Large Quantum Chemistry Model (LQCM), delivering precise quantum-mechanics level simulations that are orders of magnitude faster than other cutting-edge computational approaches. The company says BEYOND enables the pursuit of previously undruggable targets, which correspond to 80% of all proteins in the human body. Ten63 has multiple programs showing its platform can overcome previously intractable problems. One such program focuses on Myc, one of the most-studied oncogenes, which has long been considered undruggable and is believed to drive 70% of all cancers. Despite hundreds of attempts spanning 40 years, it remains elusive. With the mathematical breakthroughs behind BEYOND, Ten63 has Myc-targeting therapeutics in active development that surpass all previous attempts at Myc inhibition.

"AI not only accelerates drug discovery; it enables us to pursue high-impact targets in ways that were previously impossible. Many of the most important targets across multiple diseases are considered undruggable. These critical targets are data-poor and difficult to reach experimentally. Making them exceptionally difficult for traditional experimental screening and current AI techniques. They require a new approach," said Marcel Frenkel, PhD, CEO of Ten63 Therapeutics.

Powered by BEYOND, the company is pursuing a pipeline of first- and best-in-class small molecules against some of the most impactful oncology targets. The company is focused on high-impact, but thus far undruggable or underdrugged disease targets.

Frenkel continued, "By perfecting a simulation environment that enables AI to explore and learn from trillions of molecular possibilities, millions of times faster than physical methods, while retaining experimental-level accuracy, we are advancing towards superintelligence for drug discovery. At that point, we believe little will remain undruggable."

New investors, the Gates Foundation and Chugai Venture Fund, RYSE, K5 Global, SF Holdings, Duke Capital Partners, Cape Fear BioCapital, Black Opal Ventures, and Panorama, joined Ten63’s existing syndicate, including Hatteras Venture Partners, Yosemite, Morpheus Ventures, Alexandria Venture Investments, and Draper Associates, in the latest funding round.

In connection with the financing, Mike Dial, Ph.D., Managing Director of Chugai Venture Fund, joined Ten63’s board of directors.

Coordinated Global Effort
In connection with the investment, Ten63 also received a grant from the Gates Foundation to support a global strategy to address one of the deadliest cancers worldwide: cervical cancer.

Human papillomavirus (HPV) is the most common sexually transmitted infection in the world. Some strains of HPV are high-risk and can lead to cancers, like cervical, vulvar, and vaginal cancers. Each year, HPV causes cancer in more than 650,000 women and men. Early detection and treatment of precancerous cells can prevent this from happening. Ten63’s BEYOND platform is being used to develop cost-effective and safe treatments for HPV lesions worldwide by tackling the viral proteins that lead to cancer and have so far been undruggable.

"The enthusiasm and momentum behind this new funding validates what we’ve believed from the beginning," says Clay Thorp, Ten63 Chairman of the Board and General Partner at Hatteras Venture Partners "Ten63’s approach has the potential to transform not just cancer treatment, but the entire spectrum of drug discovery."

(Press release, Ten63 Therapeutics, FEB 19, 2026, View Source [SID1234662805])

On February 19, 2026 Olema Pharmaceuticals, Inc. ("Olema", or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, reported that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026 at 2:30 p.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast and recording of this presentation will be available, as permitted by the event host, in the Events and Presentations section of Olema’s investor relations website at ir.olema.com.

(Press release, Olema Oncology, FEB 19, 2026, View Source [SID1234662788])

On February 19, 2026 TriSalus Life Sciences, Inc. (Nasdaq: TLSI) ("TriSalus" or the "Company"), an oncology focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, reported that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering are to be sold by TriSalus. In addition, TriSalus intends to grant the underwriters a 30-day option to purchase up to 15% of the total number of shares of common stock sold in the offering, on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Lake Street Capital Markets is acting as the sole book-runner for the proposed offering.

The shares are being offered and sold by the Company pursuant to an effective shelf registration statement on Form S-3 (File No. 333-291509) previously filed with the U.S. Securities and Exchange Commission (the "SEC") on November 13, 2025 and declared effective by the SEC on December 4, 2025. The offering of such shares is being made only by means of a prospectus supplement that forms a part of the registration statement. A preliminary prospectus supplement and accompanying base prospectus relating to the offering has been or will be filed with the SEC and will be available for free on the SEC’s website at View Source When available, copies of the preliminary prospectus supplement and the accompanying base prospectus relating to the offering may be obtained from Lake Street Capital Markets, LLC at 121 South Eighth Street, Suite 1000, Minneapolis, MN 55402, or e-mail at [email protected]. The final terms of the proposed offering will be disclosed in a final prospectus supplement to be filed with the SEC.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

(Press release, TriSalus Life Sciences, FEB 19, 2026, View Source [SID1234662806])